Menu
Your Cart

Apostle Triton Bioinformatics Technology

Apostle Triton is a bioinformatics technology that utilizes the data from a curated internal cancer database of 30,000 patients with an unprecedented resolution.

Background

  • Cancer is a genetically heterogeneous disease.
  • Somatic mutations exist in both cancer and normal cells.
  • We still know very little about the genetics of cancer. There is a lacking of a comprehensive and coherent way to mine the big data repository of cancer genetics and apply the applicable findings.
  • The clinical application of liquid biopsy is further complicated by the characteristics of cell free tumor nucleic acids: low concentration, complex fragmentation, etc.

Here, we introduce Apostle Triton, a bioinformatics framework designed for liquid biopsy, which utilizes the big data from cancer genomics, evaluates disease effects of somatic mutations/variants and expression signatures, and apply the findings in the settings of liquid biopsy.

Apostle Triton Website
Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.